Evidence map›Paper›PMID 41804368›Full record

ArticleInfection and drug resistance2026

Prevalence, Antimicrobial Susceptibility, and Molecular Characteristics of Ceftazidime-Avibactam-Resistant

Jun Li, Haolan Wang, Zhaojun Liu, Yubing Xia, Yongmei Hu, Haichen Wang, Fengjun Xia, Mingxiang Zou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jun Li *Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Haolan Wang *Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Zhaojun LiuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Yubing XiaDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Yongmei HuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Haichen WangDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.
Fengjun XiaDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.ORCID 0000-0001-9871-0366
Mingxiang ZouDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The mechanisms underlying ceftazidime-avibactam resistance in carbapenem-resistant Methods: CRKP Results: In total, 67 of 623 CRKP isolates (10.8%) were identified as CRKP Conclusion: The detection rate of CRKP

Indexed as

carbapenem-resistant Klebsiella pneumoniaeceftazidime–avibactamhomologyresistance mechanism

Identifiers

PMID41804368
PMCPMC12967525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.